Psoriasis physiopathology

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue SUPPL. 2, 2006, Pages 10-23

  Jullien, Dennis ^a  

^a HÔTEL DIEU   (France)

Author keywords

Chemokines; Cytokines; Dendritic cells; Growth substances; Keratinocytes; Natural killer T lymphocytes

Indexed keywords

CD1D ANTIGEN; CHEMOKINE RECEPTOR; CYCLOSPORIN; CYCLOSPORIN A; DENILEUKIN DIFTITOX; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERLEUKIN 15; METHOTREXATE; MONOCLONAL ANTIBODY CD3; OKT 4; STAT PROTEIN; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TIOGUANINE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; DRUG MECHANISM; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY INFILTRATE; KERATINOCYTE; LANGERHANS CELL; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; PUVA; REGULATORY T LYMPHOCYTE; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ULTRAVIOLET B RADIATION;

EID: 33750365028     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01768.x     Document Type: Conference Paper

References (129)

1. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD. Psoriasis. J Am Acad Dermatol 1984; 11: 937-947.
2. Guilhou JJ, Meynadier J, Clot J. New concepts in the pathogenesis of psoriasis. Br J Dermatol 1978; 98: 585-592.
3. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447.
4. Zenz R, Eferl R, Kenner L et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005; 437: 369-375.
5. Nickoloff BJ. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 2006; 12: 102-106.
6. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
7. Ottaviani C, Nasorri F, Bedini C et al. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006; 36: 118-128.
8. Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 2005; 64: Ii30-ii36.
9. high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174: 164-173.
10. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 1990; 300: 908.
11. Gardembas-Pain M, Ifrah N, Foussard C et al. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 1990; 126: 1523.
12. Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: Further evidence for adoptive autoimmunity. Br J Dermatol 1997; 137: 130-132.
13. Genestier L, Paillot R, Fournel S et al. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-328.
14. Murphy FP, Coven TR, Burack LH et al. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. Arch Dermatol 1999; 135: 1495-1502.
15. Ozawa M, Ferenczi K, Kikuchi T et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999; 189: 711-718.
16. Urano K, Matsuyama T, Urano R, Matsuo I, Habu S. PUVA suppresses the expression of cell adhesion molecules of lymphocytes. Exp Dermatol 1995; 4: 36-41.
17. Karashima T, Hachisuka H, Sasai Y. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. J Dermatol Sci 1996; 12: 246-254.
18. Gottlieb AB, Lebwohl M, Shirin S et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43: 595-604.
19. Isaacs JD, Burrows N, Wing M et al. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997; 110: 158-166.
20. Morel P, Revillard JP, Nicolas JF et al. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 1992; 5: 465-477.
21. Prinz J, Braun-Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320-321.
22. Weinshenker BG, Bass BH, Ebers GC, Rice GP. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol 1989; 20: 1132-1133.
23. Strange P, Cooper KD, Hansen ER et al. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol 1993; 101: 695-700.
24. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155: 145-158.
25. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275: 181-189.
26. Chang JC, Smith LR, Froning KJ et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc Natl Acad Sci USA 1994; 91: 9282-9286.
27. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102: 145-149.
28. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752-759.
29. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, Ludviksson BR, Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001; 126: 365-369.
30. Pauls K, Schon M, Kubitza RC et al. Role of integrin alphaE (CD103) beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 2001; 117: 569-575.
31. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8 (+) T cells. Clin Exp Immunol 2004; 138: 83-93.
32. Bonish B, Jullien D, Dutronc Y et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000; 165: 4076-4085.
33. Cameron AL, Kirby B, Fei W, Griffiths CE. Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res 2002; 294: 363-369.
34. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 2000; 24: 212-225.
35. Motsinger A, Haas DW, Stanic AK et al. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002; 195: 869-879.
36. Cameron AL, Kirby B, Griffiths CE. Circulating natural killer cells in psoriasis. Br J Dermatol 2003; 149: 160-164.
37. van der Vliet HJ, von Blomberg BM, Nishi N et al. Circulating V (alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001; 100: 144-148.
38. Beissert S, Schwarz A, Schwarz T, Regulatory T cells. J Invest Dermatol 2006; 126: 15-24.
39. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin Immunol 2005; 17: 273-283.
40. Ginhoux F, Tacke F, Angeli V et al. Langerhans cells arise from monocytes in vivo. Nat Immunol 2006; 7: 265-273.
41. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005; 153: 945-953.
42. Cumberbatch M, Singh M, Dearman RJ et al. Impaired Langerhans cell migration in psoriasis. J Exp Med 2006; 203: 953-960.
43. Kolb-Bachofen V, Bruch-Gerharz D. Langerhans cells, nitric oxide, keratinocytes and psoriasis. Immunol Today 1999; 20: 289.
44. McKenzie RC, Weller R. Langerhans cells, keratinocytes, nitric oxide and psoriasis. Immunol Today 1998; 19: 427-428.
45. Morhenn VB. Langerhans cells may trigger the psoriatic disease process via production of nitric oxide. Immunol Today 1997; 18: 433-436.
46. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005; 23: 611-620.
47. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-694.
48. Deguchi M, Aiba S, Ohtani H, Nagura H, Tagami H. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatosesCD1a (+), factor XIIIa (+), and CD68 (+) cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. Arch Dermatol Res 2002; 294: 297-302.
49. Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996; 106: 446-453.
50. Wollenberg A, Wen S, Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry 1999; 37: 147-155.
51. Buchler T, Hajek R, Bourkova L et al. Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine 2003; 21: 877-882.
52. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-130.
53. Koga T, Duan H, Urabe K, Furue M. In situ localization of CD83-positive dendritic cells in psoriatic lesions. Dermatology 2002; 204: 100-103.
54. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102: 19057-19062.
55. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540-1543.
56. Nestle FO, Conrad C, Tun-Kyi A et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
57. Gilliet M, Conrad C, Geiges M et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-1495.
58. Wollenberg A, Wagner M, Gunther S et al. Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-1102.
59. Eriksen KW, Lovato P, Skov L et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005; 125: 936-944.
60. Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005; 11: 43-49.
61. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: An emerging role for interferon alpha. J Invest Dermatol 2005; 125: Xiv-xv.
62. Fujita H, Asahina A, Tada Y, Fujiwara H, Tamaki K. Type I interferons inhibit maturation and activation of mouse Langerhans cells. J Invest Dermatol 2005; 125: 126-133.
63. Debets R, Hegmans JP, Croughs P et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997; 158: 2955-2963.
64. Ohta Y, Katayama I, Funato T et al. In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: Interleukin-6 involved in formation of psoriatic lesions. Arch Dermatol Res 1991; 283: 351-356.
65. Kulke R, Todt-Pingel I, Rademacher D et al. Co-localized overexpression of GRO-alpha and IL-8 mRNA is restricted to the suprapapillary layers of psoriatic lesions. J Invest Dermatol 1996; 106: 526-530.
66. Ruckert R, Asadullah K, Seifert M et al. Inhibition of keratinocyte apoptosis by IL-15: A new parameter in the pathogenesis of psoriasis? J Immunol 2000; 165: 2240-2250.
67. Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis. Arch Dermatol Res 2001; 293: 334-342.
68. Otkjaer K, Kragballe K, Funding AT et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 2005; 153: 911-918.
69. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908-1915.
70. Kristensen M, Chu CQ, Eedy DJ et al. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol 1993; 94: 354-362.
71. Sirsjo A, Karlsson M, Gidlof A, Rollman O, Torma H. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol 1996; 134: 643-648.
72. Detmar M, Yeo KT, Nagy JA et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995; 105: 44-50.
73. Piepkorn M. Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases. Am J Dermatopathol 1996; 18: 165-171.
74. Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J Exp Med 1988; 167: 670-675.
75. Sugaya M, Nakamura K, Mitsui H et al. Human keratinocytes express fractalkine/CX3CL1. J Dermatol Sci 2003; 31: 179-187.
76. Schmuth M, Neyer S, Rainer C et al. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002; 11: 135-142.
77. Homey B, Alenius H, Muller A et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-165.
78. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989; 20: 617-629.
79. Denfeld RW, Hollenbaugh D, Fehrenbach A et al. CD40 is functionally expressed on human keratinocytes. Eur J Immunol 1996; 26: 2329-2334.
80. Strange P, Skov L, Baadsgaard O. Interferon gamma-treated keratinocytes activate T cells in the presence of superantigens: Involvement of major histocompatibility complex class II molecules. J Invest Dermatol 1994; 102: 150-154.
81. Bowcock AM, Krueger JG. Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711.
82. GudjoAsson JE, Elder JT. Mouse models: Psoriasis: an epidermal disease after all? Eur J Hum Genet 2006; 14: 2-4.
83. Clark RA, Chong B, Mirchandani N et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176: 4431-4439.
84. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341: 1817-1828.
85. Flier J, Boorsma DM, van Beek PJ et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194: 398-405.
86. Gillitzer R, Wolff K, Tong D et al. MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol 1993; 101: 127-131.
87. Goebeler M, Toksoy A, Spandau U et al. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998; 184: 89-95.
88. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Laboratory Invest 2001; 81: 335-347.
89. Vanbervliet B, Homey B, Durand I et al. Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: Possible role at inflamed epithelial surfaces. Eur J Immunol 2002; 32: 231-242.
90. Zhou X, Krueger JG, Kao MC et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13: 69-78.
91. Homey B, Wang W, Soto H et al. Cutting edge: The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000; 164: 3465-3470.
92. Raychaudhuri SP, Jiang WY, Farber EM et al. Upregulation of RANTES in psoriatic keratinocytes: A possible pathogenic mechanism for psoriasis. Acta Derm Venereol 1999; 79: 9-11.
93. Schon MP, Ruzicka T. Psoriasis: The plot thickens. Nat Immunol 2001; 2: 91.
94. Fraticelli P, Sironi M, Bianchi G et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-1181.
95. Raychaudhuri SP, Jiang WY, Farber EM. Cellular localization of fractalkine at sites of inflammation: Antigen-presenting cells in psoriasis express high levels of fractalkine. Br J Dermatol 2001; 144: 1105-1113.
96. Boyman O, Hefti HP, Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004; 199: 731-736.
97. Leung DY, Travers JB, Giorno R et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 1995; 96: 2106-2112.
98. Prinz JC. Psoriasis vulgaris -a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-332.
99. Travers JB, Hamid QA, Norris DA et al. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest 1999; 104: 1181-1189.
100. Vollmer S, Menssen A, Prinz JC. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: Evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol 2001; 117: 1296-1301.
101. Lin WJ, Norris DA, Achziger M, Kotzin BL, Tomkinson B. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol 2001; 117: 1546-1553.
102. Vekony MA, Holder JE, Lee AJ et al. Selective amplification of T-cell receptor variable region species is demonstrable but not essential in early lesions of psoriasis vulgaris: Analysis by anchored polymerase chain reaction and hypervariable region size spectratyping. J Invest Dermatol 1997; 109: 5-13.
103. Natter S, Seiberler S, Hufnagl P et al. Isolation of cDNA Nclones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J 1998; 12: 1559-1569.
104. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol 1997; 107: 21-24.
105. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B et al. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 1999; 117: 580-586.
106. Kobayashi H, Takahashi M, Takahashi H et al. CD4+ T-cells from peripheral blood of a patient with psoriasis recognize keratin 14 peptide but not 'homologous'streptococcal M-protein epitope. J Dermatol Sci 2002; 30: 240-247.
107. Curry JL, Qin JZ, Bonish B et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Laboratory Med 2003; 127: 178-186.
108. Aractingi S, Briand N, Le Danff C et al. HLA-G and NK receptor are expressed in psoriatic skin: A possible pathway for regulating infiltrating T cells? Am J Pathol 2001; 159: 71-77.
109. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM. IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat Immunol 2001; 2: 157-164.
110. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: Cutaneous lymphoid tissue supports T-cell activation and 'type 1'inflammatory gene expression. Trends Immunol 2004; 25: 295-305.
111. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: Modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003; 148: 670-679.
112. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-705.
113. Prinz JC, Gross B, Vollmer S et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994; 24: 593-598.
114. Chaturvedi V, Qin JZ, Denning MF et al. Apoptosis in proliferating, senescent, and immortalized keratinocytes. J Biol Chem 1999; 274: 23358-23367.
115. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity 2002; 16: 755-758.
116. Strengell M, Matikainen S, Siren J et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003; 170: 5464-5469.
117. Gutzmer R, Langer K, Mommert S et al. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol 2003; 171: 6363-6371.
118. Villadsen LS, Schuurman J, Beurskens F et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112: 1571-1580.
119. Shaker OG, Moustafa W, Essmat S, Abdel-Halim M, El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem 2006; 39: 119-125.
120. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998; 111: 1053-1057.
121. Kopp T, Lenz P, Bello-Fernandez C et al. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol 2003; 170: 5438-5444.
122. Kauffman CL, Aria N, Toichi E et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123: 1037-1044.
123. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
124. Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha, in psoriasis. Am J Pathol 1991; 138: 129-140.
125. Pine R. Convergence of TNFalpha and IFNgamma signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/ kappaB promoter element. Nucl Acids Res 1997; 25: 4346-4354.
126. Johansen C, Funding AT, Otkjaer K et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006; 176: 1431-1438.
127. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-649.
128. Tuschil A, Lam C, Haslberger A, Lindley I. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 1992; 99: 294-298.
129. Jamieson T, Cook DN, Nibbs RJ et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 2005; 6: 403-411.